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Abstract
Introduction: Dopamine is considered to be crucial for food craving and intake, drug abuse and electrical brain stimulation. Increased levels 
of dopamine occur after energy intake in the dorsal striatum. In the ventral tagmental area, dopamine is responsible for motivation. There 
is a natural synaptic dopamine level, and as a result its activity is controlled by density of receptors, amount of released neurotransmitter, 
and defectiveness of re-uptake by specific transporters. In our study, we wanted to investigate if there is a correlation between mean BMI 
values and VNTR polymorphisms in SLC6A3 (rs28363170) and DRD4 genes. 
Material and methods: Chosen gene fragments were amplified using polymerase chain reaction on the DNA template obtained from 
506 women. The products of the reaction were electrophoresed and visualised in 3% agarose gel. The genotyping data was analysed with 
Kruskal-Wallis tests (p < 0.05). 
Results: In the case of SLC6A3, statistically significant differences in mean BMI were found in the group of obese women (p < 0.05) but 
not for the whole population of women with normal weight or with overweight (p > 0.05). The mean BMI was higher for the SS genotype 
than for combined LL and LS genotypes. The difference in mean BMI values for variants of DRD4 was significant for the whole studied 
population and in the obese group (p > 0.05), and the higher value was correlated with the presence of a variant with seven or more 
repeats of 48 bp motif. 
Conclusions: When the two analysed polymorphisms were combined, the spread between the mean BMI values became greater than 
for single genes. This suggests that the effect on body mass of these two polymorphisms may combine and cause hypo-functionality of 
the dopaminergic reward system.  (Endokrynol Pol 2013; 64 (2): 101–107)
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Streszczenie
Wstęp: Dopamina jest uważana za kluczowy związek w regulacji łaknienia, przyjmowaniu pokarmów, uzależnienia od leków oraz 
w stymulacji elektrycznej mózgu. Zwiększony poziom dopaminy obserwuje się po posiłkach w grzbietowej części prążkowia. W brzusznej 
części nakrywki dopamina odpowiada za motywację. Naturalny poziom synaptyczny dopaminy wynika z gęstości receptorów, ilości 
uwolnionego neurotransmitera oraz efektywności działania systemu wychwytu zwrotnego. W niniejszym badaniu poddano analizie 
korelację wartości BMI z polimorfizmem genu DRD4 oraz polimorfizmu SLC6A3.
Materiał i metody: Wybrane fragmenty genu były zwielokratniane przy pomocy reakcji łańcuchowej polimerazy (PCR, polymerase chain 
reaction) z DNA uzyskanego od 506 kobiet. Produkty zwielokrotnienia były poddawane elektroforezie. Wyniki genotypowania analizowano 
za pomocą testu Kruskal-Wallis (P < 0,05).
Wyniki: Analizując wyniki korelacji polimorfizmu SLC6A3 istotne statystycznie różnice w zakresie wartości BMI dotyczyły jedynie kobiet 
otyłych (P < 0,05), nie potwierdzając się wśród kobiet z prawidłową i nadmierną masą ciała. Średnia wartość BMI była wyższa w przy-
padku genotypu SS, niż w zakresie rozważanych łącznie genotypów LL i LS. Różnice średnich wartości BMI w kontekście polimorfizmu 
DRD4 były istotne w całej analizowanej populacji. Wyższa wartość BMI korelowała z obecnością wariantu 7 i więcej powtórzeń motywu 
48 par zasad.
Wnioski: Prowadząc analizę łącznie korelacji z BMI dla obu polimorfizmów, istotność stawała się większa niż dla poszczególnych genów. 
Taka sytuacja może dowodzić, iż wpływ polimorfizów obu badanych genów mogą się kumulować i prowadzić do obniżenia działania 
dopaminergicznego układu nagrody. (Endokrynol Pol 2013; 64 (2): 101–107)
Słowa kluczowe: dopamina, SLC6A3, DRD4, otyłość
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Introduction
Obesity is a chronic non-infectious disease of complex 
aetiology. It is believed that environment as well as 
genetic variety may be important for its pathogenesis. 
Overweight and obesity are connected with many seri-
ous complications. Weight restriction results in multiple 
advantages, such as improvements of blood inflamma-
tory markers [1]. Obesity is defined as an excessive ac-
cumulation of body fat due to positive energy balance. 
The most useful way to assess the prevalence of obesity 
is the body mass index (BMI) defined as one’s weight 
in kilograms divided by the square of one’s height in 
metres. According to the WHO, individuals with BMI 
≥ 25 kg/m2 are considered overweight and with BMI ≥ 
30 kg/m2 obese.
Dopamine (DA) is a crucial neurotransmitter in food 
intake control. The main centres of this process are 
located in the midbrain (VTA [ventral tagmental area] 
and SNpc [substantia nigra pars compacta]) and in the 
nucleus accumbens (NAcc) located in the ventral stria-
tum (VS). Release of dopamine in VTA is responsible 
for the craving for food. Agonists which modify brain 
dopamine levels reduce further food consumption [2], 
while antagonists increase energy intake [3]. In SNpc, 
DA plays also the key role in stimulus-reward learning 
in a way that food and accompanying saliencies become 
considered as potential sources of reward [4]. The third 
role of dopamine is to stimulate the feeling of pleasure 
in the nucleus accumbens (in conjunction with the 
opioid and endocannabinoid signals) in response to 
energy intake, especially in the form of palatable food 
rich in carbohydrates and fat. Increased levels of this 
neurotransmitter can be observed after energy intake 
in the dorsal striatum NAcc [5]. 
There is a natural synaptic dopamine level, and as 
a result its activity is controlled by density of receptors, 
amount of released neurotransmitter, and defective-
ness of re-uptake by specific transporters [6-8]. In our 
study, we focused on widely analysed polymorphisms 
in genes coding dopamine transporter (SLC6A3) and 
dopamine receptor D4 (DRD4). 
Dopamine transporter (DAT), encoded by SLC6A3 
gene, is a protein responsible for DA re-uptake from 
synaptic cleft into pre-synaptic neuron, which in turn 
is the major means of termination of neurotransmission 
[9]. It consists of 12 transmembrane domains charac-
teristic for neurotransmitter transporters dependent 
on Na+ gradient (generated by Na+/K+ ATPase) and 
Cl– ions [10]. The highest level of SLC6A3 expression 
can be observed in dopaminergic neurons of VTA and 
substantia nigra (SN) [11]. These nerve cells project to 
the striatum, NAcc and prefrontal cortex [12]. In our 
study, we focused on the polymorphism rs28363170 
where alleles differ in variable number of tandem re-
peats (VNTR) in 3’-untranslated region, with the most 
common variants being 9R and 10R repeats [13]. The 
10R allele was correlated with increased expression of 
DAT in one study using the luciferase expression system 
[14] and with lowered in another [15]. It has also been 
demonstrated that allele 9R can be responsible for in-
creased availability of DAT in the human striatum [16].
The human dopamine receptor D4 is coded by the 
DRD4 gene, which is described as having a high number 
of polymorphisms [17]. In our study, we focused on 
48-bp variable number of terminal repeats (VNTR) in 
third exon, encoding 3 intracellular loop. The number 
of repeats in this region of DRD4 gene may vary from 
two to 11 repeats (2R-11R). Variants with 2R are the 
most common [18]. Furthermore, even the variants with 
the same length may differ significantly in nucleotide 
sequence [19]. It was suggested that 7R variant has 
inferior ability to reduce cyclic adenosine monophos-
phate (cAMP) compared to shorter forms [20]. The most 
significant connection of the genotype with phenotype 
was found for allele 7R and ADHD [21]. Polymorphisms 
of the DRD4 gene are considered to be crucial in the 
pathogenesis of some psychiatric disorders. However, 
a study in a Polish population showed no correlations 
of DRD4 alleles and alcoholism [22].
Material and methods
Study population characteristics
Age of subjects was 18–84 years with mean 50.7 (SD ± 
15.0). Subjects were divided into groups based on their 
body mass index (BMI; according to WHO recommen-
dation). Mean BMI for the studied population was 33.4 
(SD ± 10.0). Detailed data on BMI in different classes 
of weight is shown in Table I.
Samples collection and DNA isolation
Permission for research was granted by the Bioethics 
Committee of Nicolaus Copernicus University, Col-
legium Medicum in Bydgoszcz, Poland. Women of 
European Caucasian origin, patients and volunteers, 
were recruited at the General and Endocrinological 
Surgery Ward and the Department of Endocrinology 
and Diabetology of Collegium Medicum, Nicolaus 
Copernicus University Hospital in Bydgoszcz and at 
the Cardiological Clinic of Non-public Health Care 
Institution CITOMED in Toruń. Written consent was 
obtained from all subjects. Patients and volunteers 
were measured and weighed with standard medical 
equipment. DNA was obtained from the peripheral 
blood leukocytes from 506 women using the rapid 
DNA isolation method [23] and stored at –20 °C until 
genotyping. 
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DNA analysis 
Polymorphisms in all studied genes were analysed us-
ing the polymerase chain reaction and the agarose gel 
electrophoresis techniques.
The fragment of SLC6A3 gene was amplified using 
the forward primer 5’-TGTGGTGTAGGGAACGGCCT-
GAG-3’ and reverse primer 5’-CTTCCTGGAGGTCACG-
GCTCAAGG-3’ [24]. The reaction mixture contained 
5 pmol of each primer, 1.5 mM MgCl2 (Fermentas), 0.2 mM 
dNTP (Fermentas), 1 x (NH4)2SO4 Taq Buffer (Fermentas), 
0.5 U of Taq polymerase (Fermentas), 100 ng of DNA and 
de-ionised H20 to the final volume of 20 μL. The PCR 
programme included the following steps: initial denatura-
tion (5 min/95°C), 30 cycles of denaturation (1 min/95°C), 
annealing (1 min/62°C) and elongation (1 min/72°C), and 
a final step of elongation (2 min/72°C). The PCR product 
was electrophoresed in 2% agarose gel with ethidium 
bromide (10 μg/mL) and visualised under UV light. The 
visible bands corresponded to the S allele (443 bp) and/or 
the L allele (483 bp) depending on genotype.
The PCR products on the matrix of DRD4 gene 
were obtained using DRD4F 5’-GCGACTACGTG-
GTCTACTCG-3’ and DRD4R 5’-AGGACCCTCATGGC-
CTTGC-3’ primers [17]. The reaction mixture contained 
5 pmol of each primer, 1.5 mM MgCl2, 0.2 mM of dATP, 
dCTP and dTTP, 0.1 mM of dGTP (Fermentas), 0.1 mM 
of 7-deaza-GTP, 1 x (NH4)2SO4 Taq Buffer (Fermentas), 
0.5 U of Taq polymerase (Fermentas), 50 ng of DNA, 10% 
DMSO (Sigma) and de-ionised H2O to the final volume 
of 20 μL. The PCR protocol included the following steps: 
initial denaturation (10 min/94°C), 30 cycles of denatura-
tion (1 min/95°C), annealing (1 min/57°C) and elongation 
(1 min/72°C), and final extension (2 min/72°C). PCR prod-
ucts were electrophoresed and visualised under UV light. 
Their lengths were 379 bp in the case of 2R, 427 bp for 3R, 
475 bp for 4R, 523 bp for 5R, 571 bp for 6R and 619 bp for 
7R. The longer products were defined as 7R+.
Statistical analysis
Deviation from Hardy-Weinberg equilibrium was 
analysed using Pearson c2 test (p < 0.05) with OOoStat 
package for OpenOffice.org Calc and R v 2.12.0. [25). 
The statistical significance of differences in mean BMI 
depending on genotype for study subjects were as-
sessed by Kruskal-Wallis test (p < 0.05) implemented 
in the OOoStat package and R v 2.12.0. Analysis 
was performed for all women (A), control group (C), 
overweight group (OW), and obese in general (O) for 
two genes separately. In case of combined genotypes 
of SLC6A3 and DRD4, genes analysis was performed 
separately for the whole population (WP) and for 
women with common (frequency > 5% in WP) DRD4 
alleles (CA). 
Results
Genotype frequencies were in Hardy-Weinberg equi-
librium for both polymorphisms and for each analysed 
sub-group (control, overweight and obese). 
SLC6A3
Significant difference in mean BMI values between 
genotypes was observed in the case of obese (p = 0.033) 
under the assumption that allele L dominates. The 
mean BMI was higher for the SS genotype (43.6 ± 6.8) 
than for combined LL and LS genotypes (39.9 ± 8.2). 
There were no differences in BMI between the control 
and overweight groups. Details are shown in Table II. 
DRD4
The allele frequencies in the whole population were: 
2R — 0.090 (N = 91), 3R — 0.028 (N = 28), 4R — 0.695 
(N = 702), 5R — 0.005 (N = 5), 6R — 0.002 (N = 2), 7R 
— 0.164 (N = 166) and 7R+ — 0.016 (N = 16). When 
only women with the most common variants were 
studied, analysis of the difference in the mean BMI 
between genotypes showed that there is a correla-
tion between number of repeats and body mass index 
(p = 0.000). Women with the 2R/2R genotype had the 
lowest BMI (24.7 ± 2.8; N = 5), while those with 7R/7R 
had the highest (54.6 ± 2.7; N = 14). For other geno-
types, the mean BMI values were: 2R/7R — 27.5 ± 0.7 
Table I. Mean values and standard deviation for BMI and age in different classes of body mass
Tabela I. Średnie wartości wraz z odchyleniem standardowym dla BMI i wieku dla różnych klas masy ciała 
Body mass class (BMI range) N Mean BMI ± SD Mean age ± SD
Normal (18.5–24.9) 106 22.3 ± 1.8 50 ± 15.8
Overweight (25–29.9) 114 27.1 ± 1.4 57.5 ± 12.9
Obese (≥ 30) 286 40.1 ± 8.2 48.3 ± 14.8
Obese I (30–34.9) 92 31.9 ± 1.4 55 ± 14.6
Obese II (35–39.9) 60 36.9 ± 1.5 45.4 ± 15.8
Obese III (≥ 40) 134 47.2 ± 6.3 45 ± 12.9
BMI — body mass index; SD — standard deviation
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(N = 19), 2R/4R – 29.6 ± 10.4 (N = 248) and 4R/7R 39.3 
± 4.6 (N = 114).
The mean BMI values for the genotypes with at 
least one 7R allele or 7R+ (L) were compared to those 
with shorter alleles (S). The differences between them 
were significant in the A (p = 0.029) group and in the O 
group (p = 0.025). Genotypes with one or more L allele 
had higher mean BMI (34.9 ± 10.7 for all women and 
41.7 ± 8.8 for obese) compared to those with S (32.6 ± 
9.6 and 37.6 ± 7.7 respectively) as shown in Table II. 
SLC6A3 and DRD4
Analysis of combined polymorphisms was performed 
separately for the whole population and for women with 
the aforementioned common DRD4 alleles. Similarly to 
the single polymorphisms analysis, in the case of the 
whole population and sub-population (Table II)with the 
most common DRD4 alleles (Table III), the differences in 
mean BMI values were the most significant in the obese 
group (p = 0.027 for WP and p = 0.010 for CA). In the CA 
sub-population, the mean BMI values differed also for A 
(p = 0.038). Details are shown in Table IV. 
Discussion
Our results show that polymorphisms in SLC6A3 may 
influence BMI in the case of obese women. Higher BMI 
in this group was correlated with SS genotype. Data 
on the influence of VNTR polymorphism of SLC6A3 
gene on dopaminergic system function and eating 
disorders is inconsistent. Genotypes LS and SS are 
usually grouped together and compared to LL due to 
allele S rarity. In our study, the greatest differences were 
observed between SS and combined LL+LS in obese 
women, but not in overweight or the control group. 
This may be due to the cumulative effect of changes in 
function and activity of other elements of dopaminergic 
system. Obtained results are somehow consistent with 
the study of 90 Japanese women with diagnosed eating 
disorders (ED) compared to 115 healthy women with 
stable body weight, where frequencies of the short al-
lele were higher in the first group and associated with 
ED [26]. It has been suggested that DAT activity in the 
striatum is higher in subjects with allele S [16, 27]. In 
this case, the explanation of higher BMI in patients with 
genotype SS would be that faster removal of dopamine 
from the synaptic cleft may lead to impaired stimula-
tion of dopamine receptors in the striatum and nucleus 
accumbens in its ventral part in particular. The NAcc 
is responsible for rewarding food ingestion, and food 
richer in carbohydrates and fat (or higher amounts of it) 
may be needed to exert the same effect on the reward 
centre as in the subjects with genotype LS or LL. On the 
other hand, both lack of influence of L or S allele on the 
risk of obesity [28] or opposite dependence have been 
reported. For example, the results of a study on 88 smok-
Table II. Differences in BMI between genotypes for SLC6A3 and DRD4 
Tabela II. Różnice w BMI między genotypami dla SLC6A3 i DRD4
DAT DRD4
DAT Genotype N Mean BMI S.D. DRD4 Genotype N Mean S.D.
Whole population Whole population
LL+LS 479 33.3 9.9 LL+LS 168 34.9 10.7
SS 27 35.9 11 SS 338 32.6 9.6
p = 0.228 p = 0.029*
Control Control
LL+LS 101 22.3 1.7 LL+LS 28 22.5 1.5
SS 5 21.5 2.4 SS 78 22.1 1.8
p = 0.375 p = 0.374
Overweight Overweight
LL+LS 108 27.0 1.3 LL+LS 69 25.3 2.7
SS 6 27.5 1.8 SS 151 24.4 2.9
P = 0.551 p = 0.351
Obesity Obesity
LL+LS 270 39.9 8.2 LL+LS 99 41.7 8.8
SS 16 43.6 6.8 SS 187 39.3 7.7
p = 0.033* p = 0.025*
N — number of patients with each polymorphism
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ers by Epstein et al. [29] showed that the S allele may 
be correlated with lowered energy intake. In another 
study on 2,364 participants, the protective effect of the 
S allele on overweight and obesity was reported, though 
no data on differences between men and women, nor 
mean BMI values for the aforementioned genotypes, 
were described [30], which makes the data difficult to 
compare. In another study on 1,551 participants, the LL 
genotype was associated with increased high-calorie 
food intake in females [31].
The influence of SLC6A3 VNTR is debated. Apart 
from claims that S or L variant has higher expression, 
there is a suggestion that this polymorphism is in 
linkage disequilibrium with other functional polymor-
phisms which are in fact responsible for the observed 
associations with different phenotypes [32]. 
Our study on DRD4 VNTR conducted for the 
women with the most common alleles (2R, 4R and 7R) 
indicated that 2R/2R homozygotes had the lowest mean 
BMI value, while the carriers of two 7R alleles had the 
highest. When the alleles were clustered to the L and S 
groups, higher values of mean BMI could be observed 
when at least one copy of the L allele was present, 
especially in the obese sub-group as in the case of the 
SLC6A3 gene. The fact that allele 7R was associated 
with blunted response to dopamine may explain why 
subjects with this allele had higher mean BMI [33]. Our 
results are consistent with those reported by Levitan et 
al. who claimed that 7R allele promotes weight gain in 
women with seasonal affective disorder [34] and with 
bulimia nervosa [35] as they are susceptible to binge 
eating. The interaction between DRD4 7R and BDNF 
66Met alleles has been shown to contribute to weight 
gain in women with bulimia nervosa [36]. In addition, 
the 7R allele is connected with attention deficit hyper-
activity disorder (ADHD) or attention deficient disorder 
(ADD) [37] and it has been stated that children with 
ADHD have a higher risk of obesity development [38-
39]. In the case of ADHD, as well as obesity dopamine 
depletion and receptors, hypo-functionality may lead 
to decreased striatal activity of the dopaminergic sys-
tem, which in turn contributes to deficient inhibitory 
control of feeding, aversion to delay of food ingestion 
leading to fast-food consumption, and compensation 
of lack of reward in the striatum involved in food- and 
sex-related activities. 
The differences in BMI for genotypes of analysed 
genes, though significant, were not great and thus 
aforementioned single polymorphisms cannot be 
treated as crucial for development of obesity. However, 
when both analysed genotypes were combined, the 
spread between the highest BMI value for SS/L geno-
Table III. Differences in BMI between genotypes for SLC6A3 and DRD4 for the part of studied population with the variants 
of DRD4 with frequency higher than 5%
Tabela III. Różnice w BMI między genotypami dla genów SLC6A3 oraz DRD4 dla części populacji posiadającej allele DRD4 
występujące z częstością wyższą niż 5%
DAT DRD4
 Genotype N Mean BMI S.D. Genotype N Mean S.D.
Whole population Whole population
LL+LS 434 33.1 11.0 L 147 35.1 10.7
SS 24 37.2 9.8 S 311 32.5 9.4
p = 0.067 p = 0.023*
Control Control
LL+LS 94 22.2 1.8 L 23 22.4 1.7
SS 3 20.2 2.4 S 74 22.0 1.9
p = 0.091 p = 0.460
Overweight Overweight
LL+LS 95 27.0 1.4 L 36 27.2 2.32
SS 6 27.5 1.8 S 65 27.0 1.4
p = 0.590 p = 0.652
Obesity Obesity
LL+LS 245 39.7 8.1 L 88 41.6 9.0
SS 15 44.4 6.2 S 172 39.1 7.5
p = 0.0085** p = 0.031*
N — number of patients with each polymorphism
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type and the lowest for LL+LS/S was greater than for 
single polymorphisms. This shows that the effects of 
polymorphisms in SLC6A3 and DRD4 may synergise 
and result in impaired dopaminergic signalling. 
There are two main models explaining how dopa-
minergic system impairment may lead to overweight 
and obesity. The first proposes hyper-response of 
reward system to food intake, resulting in overeating 
in a way similar to the development of drug addiction 
[40-41]. The second assumes that reward processing is 
impaired and overfeeding is a way of compensating for 
the deficiency of dopamine signalling [42].
We believe that the results of our study support the 
theory of obesity as a result of decreased stimulation of 
reward centre resulting from DRD4 hypo-functionality 
and increased DAT activity. 
Table IV. Comparison of mean BMI for combined polymorphisms. The table on the left shows the results for the whole population 
(WP) and on the right for the sub-population with the variants of DRD4 with frequency higher than 5% (CV)
Tabela IV. Porównanie wartości BMI dla kombinacji polimorfizmów. Po lewej stronie podano wyniki dla całej populacji (WP), 
a po prawej dla części populacji posiadającej allele DRD4 występujące z częstością wyższą niż 5%
DAT/DRD4 (WP) DAT/DRD4 (CA)
 Genotype N Mean BMI S.D. Genotype N Mean S.D.
Whole population Whole population
LL+LS/L 157 34.8 10.6 LL+LS/L 136 34.9 10.7
LL+LS/S 322 32.2 9.5 LL+LS/S 298 32.3 9.3
SS/L 11 37.2 12.0 SS/L 11 37.2 12.0
SS/S 16 35.0 10.6 SS/S 13 37.0 10.6
p = 0.111 p = 0.038*
Control Control
LL+LS/L 26 22.7 1.4 LL+LS/L 21 22.6 1.6
LL+LS/S 75 22.1 1.8 LL+LS/S 73 22.1 1.9
SS/L 2 21.0 2.9 SS/L 2 20.9 2.9
SS/S 3 21.8 2.7 SS/S 1 18.7 -
p = 0.517 p = 0.230
Overweight Overweight
LL+LS/L 39 27.7 1.3 LL+LS/L 37 27.1 1.4
LL+LS/S 69 26.9 1.3 LL+LS/S 61 27.0 1.3
SS/L 2 27.9 1.6 SS/L 2 27.9 1.6
SS/S 4 27.2 2.1 SS/S 4 27.2 2.1
p = 0.728 p = 0.885
Obesity Obesity
LL+LS/L 92 41.4 8.9 LL+LS/L 81 41.4 9.1
LL+LS/S 178 39.1 7.7 LL+LS/S 164 38.9 7.4
SS/L 7 44.6 7.5 SS/L 7 44.6 7.5
SS/S 9 42.8 6.6 SS/S 8 44.3 5.3
p = 0.027* p = 0.010*
N — number of patients with each polymorphism
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